LUNGevity Foundation will accept applications for the following translational research award programs in 2024. The submission process for all programs will open on January 8, 2024.

Get more information about applying for a LUNGevity award.

Career Development Award Program: This program supports future research leaders who will keep the field of lung cancer research vibrant with new ideas. Funded projects are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy.

Hamoui Foundation / LUNGevity Clinical Research Award Program for RET-Positive Lung Cancer: This award supports high-impact research that seeks to transform the future for people diagnosed with RET-positive lung cancer. Projects funded through this program are expected to have a direct impact on the outcomes of patients with advanced RET-positive lung cancer, but innovative proposals that address other unmet needs in the RET-positive lung cancer space are also invited for submission.

RETpositive / LUNGevity Translational Research Award Program for RET-Positive Cancer: The goal of this award is to fund high-impact research that seeks to transform the future for patients diagnosed with RET-positive cancers by changing RET-positive cancers into a chronic or curable condition. Proposals focusing on multiple types of RET-positive cancers or with a clear impact on multiple types of RET-positive cancers will be given priority.